PR Newswire
EDMONTON, AB, May 27, 2022
NASDAQ | TSX: ACB
EDMONTON, AB, May 27, 2022 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, has announced today that it has amended the terms of its previously announced bought deal financing. Under the amended terms, a syndicate of underwriters led by Canaccord Genuity and BMO Capital Markets, have agreed to buy on a bought deal basis 61.2 million units of the Company (the "Units"), at a price of US$2.45 per Unit for gross proceeds of approximately US$150.0 million (the "Offering"). Each Unit will be comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant will be exercisable to acquire one common share of the Company (a "Warrant Share") for a period of 36 months following the closing date of the Offering at an exercise price of US$3.20 per Warrant Share, subject to adjustment in certain events.
The Company has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. This option may be exercised by the Underwriters for additional Units, Common Shares, Warrants or any combination of such securities. |